greeksoup/ stock research
Stock research / United States / TAK / Year to 31 March 2026

Takeda Pharmaceutical Company Limited (TAK) annual results, year to 31 March 2026: revenue JPY 4,506 billion, from the 20-F

Takeda Pharmaceutical Company Limited files a 20-F with the SEC once a year, in yen. In the year to 31 March 2026 it reported revenue of JPY 4,506 billion ($29.9 billion at the year's average rate), down 1.7% on the year before. Its profit attributable to shareholders was JPY -152 billion, and diluted earnings per share JPY -96.75.

Revenue
JPY 4,506 billion
-1.7% on the year
FY2019FY2026
Operating margin
0.1%
7.5% a year earlier
FY2019FY2026
Net income
JPY -152 billion
FY2019FY2026
Diluted EPS
JPY -96.75
FY2019FY2026

this yearthe year beforeIn yen as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2025Mar 2026
Revenue4,5824,506
Cost of sales1,5801,572
Research and development730676
Operating profit3436.2
Finance costs210358
Profit before tax175-142
Income tax66.99.8
Profit for the year108-152
Profit attributable to shareholders108-152
Filing20-F20-F
JPY billion, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2025Mar 2026
Diluted EPS67.23-96.75
Basic EPS68.36-96.75
Filing20-F20-F

JPY per ordinary share, as filed.

Cash flow

Year toMar 2025Mar 2026
Cash from operations1,0571,041
Purchase of property, plant and equipment201176
Free cash flow856865
Cash from investing-367-369
Cash from financing-751-497
Depreciation and amortisation761721
Buybacks51.951.6
Dividends paid302312
Filing20-F20-F

JPY billion. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2025Mar 2026
Funded by
Equity attributable to shareholders6,9357,429
Non-controlling interests0.91.2
Borrowings, as filed4,5154,882
Lease liabilities573595
Other liabilities2,2242,604
Total equity and liabilities14,24815,512
Owned
Property, plant and equipment1,9682,121
Goodwill5,3245,809
Other intangible assets3,6323,419
Cash and cash equivalents385595
Trade and other receivables709844
Inventories1,2171,397
Other assets1,0121,327
Total assets14,24815,512
Filing20-F20-F

JPY billion, at each fiscal year end.

Ratios on the filed lines

Year toMar 2025Mar 2026
Operating margin7.5%0.1%
Net margin2.4%-3.4%
Free cash flow margin18.7%19.2%
Return on year-end equity1.6%-2.1%
Effective tax rate38.2%n/a
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2026, filed 17 June 2026: the filing. The figures are in yen as filed.